Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06097195Not ApplicableRecruiting

The Clinical Utility of BioEP in Diagnostic Decision Making in Epilepsy

Role: lead

NCT06669364Not Yet Recruiting

A Retrospective Study to Validate BioEP as an Assessment Aid for Seizure Susceptibility

Role: lead

NCT06354868Not Yet Recruiting

A Study to Assess utiLity of BIoEP as an Early Prognostic Indicator for Predicting Anti-Seizure Medication (ASM) Efficacy

Role: lead

NCT05764252Active Not Recruiting

A Prospective Diagnostic Belief Updating Study to verIfy the Utility of BioEP in First Seizure Clinics.

Role: lead

NCT06546410Not Yet Recruiting

OASIS: RetrOspective Analysis on EEGs for Identifying Seizure Susceptibility in paediatrIcs Using biomarkerS

Role: lead

NCT05384782Completed

Computational Decision Support in Epilepsy Using Retrospective EEG

Role: collaborator

All 6 trials loaded